vs
拜玛林制药（BMRN）与ROKU, INC（ROKU）财务数据对比。点击上方公司名可切换其他公司
ROKU, INC的季度营收约是拜玛林制药的1.4倍（$1.2B vs $874.6M），ROKU, INC净利率更高（-2.2% vs -5.3%，领先3.1%），拜玛林制药同比增速更快（17.0% vs -18.3%），ROKU, INC自由现金流更多（$298.4M vs $58.9M），过去两年拜玛林制药的营收复合增速更高（16.1% vs 13.6%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
Roku是美国流媒体技术企业，2002年由安东尼·伍德创立，主营数字媒体播放器、电视硬件生产，流媒体内容分发及平台广告运营。截至2024年覆盖用户达1.45亿，是美国流媒体视频分发领域的市场领导者，业务覆盖澳、加、法、德、英及拉美多国。
BMRN vs ROKU — 直观对比
营收规模更大
ROKU
是对方的1.4倍
$874.6M
营收增速更快
BMRN
高出35.3%
-18.3%
净利率更高
ROKU
高出3.1%
-5.3%
自由现金流更多
ROKU
多$239.5M
$58.9M
两年增速更快
BMRN
近两年复合增速
13.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $1.2B |
| 净利润 | $-46.6M | $-27.4M |
| 毛利率 | 68.5% | 35.6% |
| 营业利润率 | -5.1% | 59.7% |
| 净利率 | -5.3% | -2.2% |
| 营收同比 | 17.0% | -18.3% |
| 净利润同比 | -137.3% | -361.0% |
| 每股收益（稀释后） | $-0.22 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNROKU
| Q1 26 | — | $1.2B | ||
| Q4 25 | $874.6M | $1.4B | ||
| Q3 25 | $776.1M | $1.2B | ||
| Q2 25 | $825.4M | $1.1B | ||
| Q1 25 | $745.1M | $1.0B | ||
| Q4 24 | $747.3M | $1.2B | ||
| Q3 24 | $745.7M | $1.1B | ||
| Q2 24 | $712.0M | $968.2M |
净利润BMRNROKU
| Q1 26 | — | $-27.4M | ||
| Q4 25 | $-46.6M | $80.5M | ||
| Q3 25 | $-30.7M | $24.8M | ||
| Q2 25 | $240.5M | $10.5M | ||
| Q1 25 | $185.7M | $-27.4M | ||
| Q4 24 | $124.9M | $-35.5M | ||
| Q3 24 | $106.1M | $-9.0M | ||
| Q2 24 | $107.2M | $-34.0M |
毛利率BMRNROKU
| Q1 26 | — | 35.6% | ||
| Q4 25 | 68.5% | 43.5% | ||
| Q3 25 | 82.0% | 43.4% | ||
| Q2 25 | 81.8% | 44.8% | ||
| Q1 25 | 79.7% | 43.6% | ||
| Q4 24 | 81.8% | 42.7% | ||
| Q3 24 | 74.7% | 45.2% | ||
| Q2 24 | 81.7% | 43.9% |
营业利润率BMRNROKU
| Q1 26 | — | 59.7% | ||
| Q4 25 | -5.1% | 4.7% | ||
| Q3 25 | -6.0% | 0.8% | ||
| Q2 25 | 33.5% | -2.1% | ||
| Q1 25 | 30.0% | -5.7% | ||
| Q4 24 | 21.6% | -3.3% | ||
| Q3 24 | 15.3% | -3.4% | ||
| Q2 24 | 16.9% | -7.4% |
净利率BMRNROKU
| Q1 26 | — | -2.2% | ||
| Q4 25 | -5.3% | 5.8% | ||
| Q3 25 | -4.0% | 2.0% | ||
| Q2 25 | 29.1% | 0.9% | ||
| Q1 25 | 24.9% | -2.7% | ||
| Q4 24 | 16.7% | -3.0% | ||
| Q3 24 | 14.2% | -0.9% | ||
| Q2 24 | 15.1% | -3.5% |
每股收益（稀释后）BMRNROKU
| Q1 26 | — | $0.57 | ||
| Q4 25 | $-0.22 | $0.55 | ||
| Q3 25 | $-0.16 | $0.16 | ||
| Q2 25 | $1.23 | $0.07 | ||
| Q1 25 | $0.95 | $-0.19 | ||
| Q4 24 | $0.65 | $-0.24 | ||
| Q3 24 | $0.55 | $-0.06 | ||
| Q2 24 | $0.55 | $-0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $2.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.1B | $2.7B |
| 总资产 | $7.6B | $4.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRNROKU
| Q1 26 | — | $2.4B | ||
| Q4 25 | $1.3B | $2.3B | ||
| Q3 25 | $1.3B | $2.3B | ||
| Q2 25 | $1.2B | $2.3B | ||
| Q1 25 | $1.0B | $2.3B | ||
| Q4 24 | $942.8M | $2.2B | ||
| Q3 24 | $675.4M | $2.1B | ||
| Q2 24 | $972.1M | $2.1B |
股东权益BMRNROKU
| Q1 26 | — | $2.7B | ||
| Q4 25 | $6.1B | $2.7B | ||
| Q3 25 | $6.1B | $2.6B | ||
| Q2 25 | $6.0B | $2.6B | ||
| Q1 25 | $5.8B | $2.5B | ||
| Q4 24 | $5.7B | $2.5B | ||
| Q3 24 | $5.4B | $2.5B | ||
| Q2 24 | $5.3B | $2.4B |
总资产BMRNROKU
| Q1 26 | — | $4.4B | ||
| Q4 25 | $7.6B | $4.4B | ||
| Q3 25 | $7.6B | $4.4B | ||
| Q2 25 | $7.5B | $4.3B | ||
| Q1 25 | $7.1B | $4.2B | ||
| Q4 24 | $7.0B | $4.3B | ||
| Q3 24 | $6.9B | $4.3B | ||
| Q2 24 | $7.1B | $4.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $199.1M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $298.4M |
| 自由现金流率自由现金流/营收 | 6.7% | 23.9% |
| 资本支出强度资本支出/营收 | 4.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | $640.0M |
8季度趋势，按日历期对齐
经营现金流BMRNROKU
| Q1 26 | — | $199.1M | ||
| Q4 25 | $99.6M | $107.7M | ||
| Q3 25 | $368.7M | $127.6M | ||
| Q2 25 | $185.3M | $109.7M | ||
| Q1 25 | $174.4M | $138.7M | ||
| Q4 24 | $185.6M | $79.3M | ||
| Q3 24 | $221.5M | $68.7M | ||
| Q2 24 | $118.8M | $23.4M |
自由现金流BMRNROKU
| Q1 26 | — | $298.4M | ||
| Q4 25 | $58.9M | $106.6M | ||
| Q3 25 | $340.2M | $126.5M | ||
| Q2 25 | $168.2M | $108.6M | ||
| Q1 25 | $157.6M | $136.8M | ||
| Q4 24 | $166.1M | $76.8M | ||
| Q3 24 | $203.0M | $67.6M | ||
| Q2 24 | $97.4M | $22.5M |
自由现金流率BMRNROKU
| Q1 26 | — | 23.9% | ||
| Q4 25 | 6.7% | 7.6% | ||
| Q3 25 | 43.8% | 10.4% | ||
| Q2 25 | 20.4% | 9.8% | ||
| Q1 25 | 21.2% | 13.4% | ||
| Q4 24 | 22.2% | 6.4% | ||
| Q3 24 | 27.2% | 6.4% | ||
| Q2 24 | 13.7% | 2.3% |
资本支出强度BMRNROKU
| Q1 26 | — | — | ||
| Q4 25 | 4.7% | 0.1% | ||
| Q3 25 | 3.7% | 0.1% | ||
| Q2 25 | 2.1% | 0.1% | ||
| Q1 25 | 2.3% | 0.2% | ||
| Q4 24 | 2.6% | 0.2% | ||
| Q3 24 | 2.5% | 0.1% | ||
| Q2 24 | 3.0% | 0.1% |
现金转化率BMRNROKU
| Q1 26 | — | — | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 5.14× | ||
| Q2 25 | 0.77× | 10.45× | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 1.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
ROKU
| Advertising | $612.7M | 49% |
| Subscriptions | $518.5M | 42% |
| Devices | $117.6M | 9% |
